13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Frankfurt |
90,840 |
05.06.24 12:59:36 |
+0,360 |
+0,40% |
0,000 |
0,000 |
90,540 |
90,840 |
|
REGENERON PHARMAC.DL-,001 |
881535 |
Frankfurt |
920,000 |
05.06.24 10:07:49 |
+7,400 |
+0,81% |
0,000 |
0,000 |
910,000 |
920,000 |